Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
BACKGROUND
Whether patients with resectable colorectal liver metastases (CRLM) receive survival benefit from neoadjuvant chemotherapy remains controversial.


METHODS
We retrospectively analyzed 466 patients with resectable CRLM between 2000 and 2010. Patient characteristics and survival data were recorded.


RESULTS
The patients were divided into one group with neoadjuvant chemotherapy (group NC, n = 121) and another without (group WN, n = 345). There was no difference in 5-year survival (52% vs. 48%) between the two groups. No significant differences were identified between the two groups in terms of 30-day mortality (1.7% vs. 1.2%) or morbidity (33.9% vs. 25.8%). A primary tumor at stage T4, ≥4 liver metastases, the largest liver metastasis ≥5 cm in diameter, and a serum CEA level ≥5 ng/ml were independent prognostic factors. By assigning one point to each, the patients were divided into a low-risk group (0-2) and a high-risk (3-4). The patients in the low-risk group received no survival benefit from neoadjuvant chemotherapy, whereas those in the high-risk group received survival benefit (5-year survival, 39% vs. 33%, P = 0.028).


CONCLUSIONS
Preoperative neoadjuvant chemotherapy did not increase mortality or complications. Not all resectable patients, only those with >2 independent risk factors, received survival benefit from neoadjuvant chemotherapy.
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Dexiang
D
Zhu
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunshi
Y
Zhong
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Ye
Y
Wei
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Lechi
L
Ye
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qi
Q
Lin
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Li
L
Ren
Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qinghai
Q
Ye
Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Tianshu
T
Liu
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianmin
J
Xu
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinyu
X
Qin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome